3-(1H-咪唑-4-基)苯胺 | 83184-01-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 3-(1H-咪唑-4-基)苯胺
• 英文名称: 5-(3-aminophenyl)-3H-imidazole
• 英文别名: 4(5)-(3-aminophenyl)-1H-imidazole；3-(1H-imidazol-4-yl)aniline；4-(3-aminophenyl)imidazole；3-(1H-imidazol-5-yl)aniline
• CAS: 83184-01-4
• 化学式: C₉H₉N₃
• mdl: MFCD08688824
• 分子量: 159.191
• InChiKey: OEIQSFWIRHWDIL-UHFFFAOYSA-N

物化性质

• 沸点：
  487.3±28.0 °C(Predicted)
• 密度：
  1.238±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54.7
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933290090

反应信息

• 作为反应物：
  描述：

  3-(1H-咪唑-4-基)苯胺 以 乙醇 、 水 为溶剂， 生成 N-[3-(1H-Imidazol-4-yl)-phenyl]-N'-methyl-formamidine
  参考文献：
  名称：

  (Imidazolylphenyl)formamidines. A structurally novel class of potent histamine H2 receptor antagonists

  摘要：

  Structure-activity considerations of N alpha-guanylhistamine, the first compound found with detectable H2-antagonist activity, led to the synthesis of a series of conformationally rigid guanylhistamine analogues, namely, (imidazolylphenyl)guanidines, imidazolylbenzamidines, and (imidazolylphenyl)formamidines. It was found that in the guanidine and benzamidine classes, the meta-substituted derivatives (3, 4, 7, and 8) possessed H2-antagonist activity, whereas in the class of formamidines, only the para-substituted derivative 10 was found active. A subsequent increase in the size of the substituent at the formamidino group of 10 led to compounds (15-20) of high H2-antagonist affinity, which was related to the gastric antisecretory effect. Members of this structurally novel class of H2 antagonists were 20- to 50-fold more potent than cimetidine both "in vitro" and "in vivo". Structure-activity relationships are discussed in terms of ionization properties, partitioning behavior, conformational aspects of the selected compound 17, and of possible modes of interaction with the histamine H2 receptor. It was found that the formamidine moiety was an important structural feature and that H2-antagonist activity requires correct steric and electronic properties. Compound 17 (DA 4577), owing to its pharmacological profile and demonstrated safety in animals, was selected to be clinically investigated.

  DOI：

  10.1021/jm00369a025
• 作为产物：
  描述：

  5-(3-硝基苯基)-1H-咪唑 在 palladium on activated charcoal 氢气 作用下， 以 甲醇 为溶剂， 反应 3.0h， 生成 3-(1H-咪唑-4-基)苯胺
  参考文献：
  名称：

  Molecular conformations of aminophenylimidazoles exhibiting antiulcer activities.

  摘要：

  为了通过实验澄清 H2 受体拮抗剂可能存在的立体结构-活性关系，我们合成了三种 5-氨基苯基咪唑（1、2 和 3），其中的氨基分别位于苯环的正位、偏位和对位，并使用 X 射线衍射和质子核磁共振（1H-NMR）方法检测了它们的构象特征，以及在大鼠身上的抗溃疡活性和在豚鼠身上的 H2 受体拮抗剂活性。正交异构体 1 优先形成分子内 N-H（氨基）......N（咪唑）氢键，显示出最高的抗溃疡活性，药效是西咪替丁的一半。另一方面，1、2 和 3 均未显示出明显的 H2 受体拮抗剂活性。基于这些结果，我们对显示抗溃疡活性的构象特征进行了讨论。

  DOI：

  10.1248/cpb.38.1803

文献信息

• Mnk1 or Mnk2 inhibitors
  申请人：DeveloGen Aktiengesellschaft

  公开号：EP1746099A1

  公开（公告）日：2007-01-24

  The present invention relates to novel pharmaceutical compositions comprising pyrazolopyrimidine compounds. Moreover, the present invention relates to the use of the pyrazolopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.

  本发明涉及包含吡唑并嘧啶化合物的新型药物组合物。此外，本发明涉及利用本发明的吡唑并嘧啶化合物制备用于预防和/或治疗可能受到Mnk1和/或Mnk2（Mnk2a或Mnk2b）的激酶活性抑制影响的疾病的药物组合物。
• Synthesis and Histamine H3 and H4 Receptor Activity of Conformationally Restricted Cyanoguanidines Related to UR-PI376
  作者：Roland Geyer、Armin Buschauer

  DOI：10.1002/ardp.201100144

  日期：2011.12

  Recently, we identified highly potent agonists of the human histamine H4 receptor (hH4R) among a series of imidazolylbutylcyanoguanidines. Aiming at improved selectivity for the hH4R relative to the H3 receptor (hH3R), the flexible tetramethylene linker connecting imidazole ring and cyanoguanidine group was replaced by conformationally restricted carbocycles. Introduction of a para‐ or a meta‐phenylene

  最近，我们在一系列咪唑基丁基氰基胍中鉴定了人类组胺 H4 受体 (hH4R) 的高效激动剂。为了提高 hH4R 相对于 H3 受体 (hH3R) 的选择性，连接咪唑环和氰基胍基团的柔性四亚甲基接头被构象限制的碳环取代。在 hH3R 和 hH4R 中引入对位或间亚苯基间隔物仅产生非常弱的活性化合物（在 [35S]GTPγS 结合测定中使用表达 hHxR 亚型的 Sf9 昆虫细胞膜进行研究）。相比之下，加入更灵活的环己烷-1,4-二基接头导致 hH4R 和 hH3R 处的 EC50 或 KB 值≥110 nM。所研究化合物的作用质量、效力和受体亚型选择性取决于立体化学：顺式构型的非对映异构体更喜欢 hH4R 并且是部分激动剂，而反式异构体则是 hH4R 的拮抗剂。在 hH3R 上，反式非对映异构体优于顺式异构体的 10 倍。咪唑基环烷基氰基胍的结果表明，环大小的变化和立体化学的优化可能有助于提高
• [EN] 2-(4-((5-(BENZO[B]THIOPHEN-3-YL)-1H-TETRAZOL-1-YL)METHYL)PHENYL)-5-(DIFLUOROMETHYL)-1,3,4-OXADIAZOLE DERIVATIVES AND SIMILAR COMPOUNDS AS SELECTIVE INHIBITORS OF HISTONE DEACETYLASE 6 (HDAC6) FOR USE IN TREATING E.G. PERIPHERAL NEUROPATHY<br/>[FR] DÉRIVÉS DE 2-(4-((5-(BENZO[B]THIOPHÉN-3-YL)-1H-TÉTRAZOL-1-YL)MÉTHYL)PHÉNYL)-5-(DIFLUOROMÉTHYL)-1,3,4-OXADIAZOLE ET COMPOSÉS SIMILAIRES EN TANT QU'INHIBITEURS SÉLECTIFS DE L'HISTONE DÉSACÉTYLASE 6 (HDAC6) POUR UNE UTILISATION DANS LE TRAITEMENT, PAR EXEMPLE, DE LA NEUROPATHIE PÉRIPHÉRIQUE
  申请人：ITALFARMACO SPA

  公开号：WO2022029041A1

  公开（公告）日：2022-02-10

  Compounds of formula (I) as selective inhibitors of histone deacetylase 6 (HDAC6) for use in treating e.g. peripheral neuropathy, graft rejection, GVHD, myositis, diseases associated with abnormal lymphocyte function, multiple myeloma, non-Hodgkin lymphoma, autoimmune diseases, inflammatory diseases, cancer and neurodegenerative pathologies. Preferred compounds are e.g. 2-(4-((5-(benzo[b]thiophen-3-yl)-1H- tetrazol-1-yl)methyl)phenyl)-5-(difluoromethyl)-1,3,4-oxadiazole derivatives and related compounds.

  公式为（I）的化合物是选择性组织脱乙酰化酶6（HDAC6）抑制剂，用于治疗外周神经病、移植排斥、GVHD、肌炎、与异常淋巴细胞功能相关的疾病、多发性骨髓瘤、非何杰金淋巴瘤、自身免疫性疾病、炎症性疾病、癌症和神经退行性病理学。首选化合物是例如2-（4-（（5-（苯并[b]噻吩-3-基）-1H-四唑-1-基）甲基）苯基）-5-（二氟甲基）-1,3,4-噁唑衍生物及相关化合物。
• Heterobicyclic derivatives
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：US20020107251A1

  公开（公告）日：2002-08-08

  Heterobicyclic derivatives of the formula: 1 wherein R 1 is aryl which may have suitable substituent(s), ar(lower)alkyl which may have suitable substituent(s), halo(lower)alkyl, protected carboxy(lower)alkyl, acyl(lower)alkyl, heterocyclic group or heterocyclic(lower)alkyl which may have suitable substituent(s), R 2 is aryl which may have suitable substituent(s) or heterocyclic group, and R 3 is hydrogen, lower alkoxy or arylthio, and a pharmaceutically acceptable salt thereof which are useful as a medicament.

  公式为1的杂环双环衍生物，其中：R1是苯基，可以具有适当的取代基；芳基（较低）烷基，可以具有适当的取代基；卤代（较低）烷基；保护的羧基（较低）烷基；酰基（较低）烷基；杂环基或者可以具有适当的取代基的杂环（较低）烷基；R2是苯基，可以具有适当的取代基或者杂环基；R3是氢、较低烷氧基或者芳基硫醚。它们的药物可接受盐是有用的。
• Indolinones having kinase-inhibiting activity
  申请人：Boehringer Ingelheim Pharma KG

  公开号：US06043254A1

  公开（公告）日：2000-03-28

  The present invention relates to indolinones of general formula ##STR1## wherein R.sub.1 to R.sub.3 are defined in claim 1, the isomers and the salts thereof, particularly the physiologically acceptable salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on various kinases and cycline/CDK complexes and on the proliferation of various tumour cells, pharmaceutical compositions containing these compounds, their use and processes for preparing them.

  本发明涉及一般式为##STR1##的吲哚酮，其中R.sub.1到R.sub.3在权利要求1中定义，其异构体和盐，特别是具有有价值的药理学特性的生理学上可接受的盐，特别是对各种激酶和环/ CDK复合物以及各种肿瘤细胞增殖具有抑制作用的药物组合物，这些化合物的使用和制备过程。